Maegim한국어

부광약품

003000KOSPISector: Pharma & Biotech
₩3,755▲ 0.13%Market cap ₩370.5BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.2 ptsTop 15% of 2,523 stocks
Financial strength
66.8
Growth momentum
78.3
Price attractiveness
62.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

66.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
39.7%
✓ Above median · Top 38% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
257.3%
✓ Above median · Top 38.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
7.1%
✓ Above median · Top 24.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
3.7%
✓ Above median · Top 31.5% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

78.3
How much did revenue grow in a year?
Revenue growth (YoY)
25.4%
✓ Above median · Top 20.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
1.7%
✗ Below median · Top 63.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
775.6%
✓ Above median · Top 2.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
6241.2%
✓ Above median · Top 0.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

62.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
29.5x
✓ Above median · Top 31.1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.09x
✓ Above median · Top 43.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15